Loncastuximab tesirine targets CD19 on B cells, is internalized, and releases a PBD payload that crosslinks DNA at the N2 of guanine in the minor groove, blocking replication and causing cell death. DNA is the intracellular pharmacologic site, not the selecting target; only CD19+ cells are killed.